高级检索
    郭爱林, 宗飒. HKI-272和雷帕霉素联合治疗克服非小细胞肺癌EGFR-TKI获得性耐药[J]. 循证医学, 2008, 8(4): 210-212. DOI: 10.3969/j.issn.1671-5144.2008.04.005
    引用本文: 郭爱林, 宗飒. HKI-272和雷帕霉素联合治疗克服非小细胞肺癌EGFR-TKI获得性耐药[J]. 循证医学, 2008, 8(4): 210-212. DOI: 10.3969/j.issn.1671-5144.2008.04.005
    shu
    GUO Ai-lin, ZONG Sa. HKI-272 and Rapamycin Combination Therapy Overcome the Acquired Resistance of EGFR-TKI in Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2008, 8(4): 210-212. DOI: 10.3969/j.issn.1671-5144.2008.04.005
    Citation: GUO Ai-lin, ZONG Sa. HKI-272 and Rapamycin Combination Therapy Overcome the Acquired Resistance of EGFR-TKI in Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2008, 8(4): 210-212. DOI: 10.3969/j.issn.1671-5144.2008.04.005
    shu

    HKI-272和雷帕霉素联合治疗克服非小细胞肺癌EGFR-TKI获得性耐药

    HKI-272 and Rapamycin Combination Therapy Overcome the Acquired Resistance of EGFR-TKI in Non-Small Cell Lung Cancer

      摘要
      • HTML全文
      • 参考文献(0)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回